Wrappable sterile radiation shield drape, combination of a radiation shield and sterile drape therefor and method of providing a sterile drape about a radiation shield

A wrappable sterile radiation shield drape, a wrappable sterile radiation shield drape in combination with a radiation shield, and a method of providing a sterile surface about a suspended radiation shield is provided. The drape includes a flexible wall having a sterilized outer surface. The wall has opposite side edges extending between upper and lower ends. The upper end has an everted portion providing an inverted pocket. The wall includes an upper fastener adjacent its upper end. The upper fastener is configured to releasably fix the upper end of the wall relative to the radiation shield. The wall further includes an edge fastener adjacent at least one of its side edges. The edge fastener is configured for releasable attachment adjacent the opposite side edge to releasably maintain the wall in a wrapped configuration about the radiation shield with the side edges being releasably maintained in overlapping relation with one another.

Master/slave arrangement of an electronic engine control device with engine identification module

A master/slave arrangement of an electronic engine control device with an engine identification module. The electronic engine control device controls and regulates the internal combustion machine. The engine identification module includes at least one microprocessor and a memory building block for storing an engine identification as well as engine specifics. The electronic engine control device and the engine identification module exchange data through an engine cable harness. The engine identification module is arranged inseparably at the crank housing of the internal combustion machine. The engine identification module can be removed from the crank housing as well as from the engine cable harness only by being destroyed.

FLUORESCENT pH DETECTOR SYSTEM AND RELATED METHODS

Fluorescent pH detector and methods for measuring pH using the fluorescent pH detector.

PRODUCTION OF POLYUNSATURATED FATTY ACIDS BY COEXPRESSION OF ACYL-CoA:LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES AND PHOSPHOLIPID:DIACYLGLYCEROL ACYLTRANSFERASES

Acyl-CoA:lysophosphatidylcholine acyltransferase [“LPCAT”] having the ability to convert acyl-CoA+1-acyl-sn-glycero-3-phosphocholine to CoA+1,2-diacyl-sn-glycero-3-phosphocholine (EC 2.3.1.23) is disclosed herein to be over-expressed along with the over-expression of phospholipid:diacylglycerol acyltransferase [“PDAT”] having the ability to transfer a fatty acyl group from the sn-2 position of a phospholipid (e.g., phosphatidylcholine) to the sn-3 position of 1,2-diacylglycerol [E.C.2.3.1.158], thus resulting in a lysophospholipid and TAG. Co-expression of these enzymes in a recombinant microbial host cell resulted in increased production of long chain polyunsaturated fatty acids [“PUFAs”].

MUTANT ACYL-CoA:LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES

Mutant acyl-CoA:lysophosphatidylcholine acyltransferases [“LPCATs”] having the ability to convert acyl-CoA+1-acyl-sn-glycero-3-phosphocholine to CoA+1,2-diacyl-sn-glycero-3-phosphocholine (EC 2.3.1.23) are disclosed herein. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding mutant LPCATs, along with a method of making long chain polyunsaturated fatty acids [“PUFAs”] using these mutant LPCATs in oleaginous yeast, are also disclosed.

Network-related performance for gpus

Techniques for improved networking performance in systems where a graphics processing unit or other highly parallel non-central-processing-unit (referred to as an accelerated processing device or “APD” herein) has the ability to directly issue commands to a networking device such as a network interface controller (“NIC”) are disclosed. According to a first technique, the latency associated with loading certain metadata into NIC hardware memory is reduced or eliminated by pre-fetching network command queue metadata into hardware network command queue metadata slots of the NIC, thereby reducing the latency associated with fetching that metadata at a later time. A second technique involves reducing latency by prioritizing work on an APD when it is known that certain network traffic is soon to arrive over the network via a NIC.

Furan based polyamides

Disclosed herein are compositions and article made therefrom and processes of making them. The composition comprises a polymer, the polymer comprising a repeat unit of formula shown below: wherein the polymer is derived from an aromatic diamine comprising m-phenylene diamine, and an aromatic diacid or a derivative thereof comprising furan dicarboxylic acid or derivative thereof.

Method for operating an internal combustion engine, internal combustion engine and maintenance system for an internal combustion engine, self-executable computer program product and non-volatile storage medium

A method for operating an internal combustion engine having a hardware structure including an engine control unit and a maintenance unit, an electronic engine identification module and an engine control program, the method having the steps: providing a computer program product via a network by which an engine identification and engine data are loaded together and are exchanged, wherein the computer program product is designed for uploading and/or downloading a maintenance software module by which the engine identification and the engine data are compiled; loading the computer program product onto a non-volatile storage medium; coupling the non-volatile storage medium to the maintenance unit of the hardware structure and executing the computer program product; exchanging the maintenance software module between the non-volatile storage medium and the maintenance unit; identifying the engine and compiling engine data by the maintenance software module and a hardware component of the hardware structure.

Wrappable sterile radiation shield drape, combination of a radiation shield and sterile drape therefor and method of providing a sterile drape about a radiation shield

A wrappable sterile radiation shield drape, a wrappable sterile radiation shield drape in combination with a radiation shield, and a method of providing a sterile surface about a suspended radiation shield is provided. The drape includes a flexible wall having a sterilized outer surface. The wall has opposite side edges extending between upper and lower ends and an upper fastener adjacent its upper end. The upper fastener is configured to releasably fix the upper end of the wall relative to the radiation shield. The wall further includes an edge fastener adjacent at least one of its side edges. The edge fastener is configured to releasably maintain the wall in a wrapped configuration about the radiation shield. The wall further includes at least one flap attached adjacent the upper end, wherein the flap includes a pocket configured to receive a shoulder extension portion of the radiation shield.

Methods of Suppressing Rheumatoid Arthritis Using an Anti-IL-6 Antibody

Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

System and method for consistent paper movement

A system and method for consistent paper movement includes a pick/feed motor configured to rotate a pick/feed roller of a print engine to deliver a sheet of paper to the registration nip of a registration roller. A first sensor and a second sensor disposed in the paper path between the pick/feed roller and the registration roller detect the leading edge of the paper. A controller receives sensor data from the first and second sensors and compares the sensor data with expected times for receiving the sensor data. When the received sensor data indicates that the paper is lagging or leading, the controller calculates a period of time to drive the drive the pick/feed motor at a higher or lower speed to compensate for the lagging or leading of the paper.

Methods for expressing polypeptides in hyperthermophiles

Provided herein are genetically engineered archaea. A genetically engineered archaea includes a heterologous polynucleotide that has a promoter operably linked to a coding region, where the coding region encodes a polypeptide having optimal activity below the optimum growth temperature (T opt ) of the genetically engineered archaeon. Also provided herein are methods for using genetically engineered archaea and cell-free extracts of such genetically engineered archaea. In one embodiment, the methods include culturing a genetically engineered archaeon at a temperature that is at least 20° C. below the T opt of the genetically engineered archaeon, such that the activity in the genetically engineered archaeon of a polypeptide encoded by the coding region is increased compared to the activity in the genetically engineered archaeon of the polypeptide during growth at a second temperature that is at or near the T opt of the genetically engineered archaeon.

Angled ridges on electrostatic process unit shafts

A system and method for urging stray toner away from sealing areas on rotating shafts in electrostatic process units includes a shaft that is associated with a rotating component of the electrostatic process unit such as a toner mixer, a waste auger, a developer, or a photoconductive drum. The shaft includes sealing areas at either end of the shaft that are configured to prevent toner leakage through the sealing areas, and protruding ridges in the sealing areas that encircle the shaft. The protruding ridges are angled relative to the axis of the shaft such that rotation of the shaft causes the protruding ridges to urge stray toner away from the sealing areas. The protruding ridges substantially reduce toner leakage through the sealing areas of rotating shafts of electrostatic process units.

Genetically engineered microbes and methods for converting organic acids to alcohols

Disclosed herein are genetically engineered microbes. In one embodiment, a genetically engineered microbe includes a metabolic pathway for the production of an alcohol from an organic acid. For instance, a genetically engineered microbe converts acetate, butyrate, propionate, isobutyrate, valerate, isovalerate, caproate, or phenylacetate, to Ethanol, Butanol, Propanol, Isobutanol, 1-Pentanol, Isoamylalcohol, 1-Hexanol, Phenylethanol, respectively. Also provided herein are methods of using the microbes.

Print manager system and method for printer selection

A system and method for monitoring and managing printers includes receiving printer status data associated with a user print job from two or more networked multifunction peripherals. Print job data is compared to the received printer status data. A multifunction peripheral for executing the user's print job is identified in accordance with the comparison. Data identifying the multifunction peripheral includes a subset of the printer status data associated with the identified multifunction peripheral.

Grip tape for a sports implement

A grip for use with a sports implement extending about a longitudinal axis. The grip includes a flexible strip defining a length defining a major dimension and width defining a minor dimension. The strip has a butt end region, a primary region and a throat end region. The throat end region defines at least one guideline. The guideline extends along an outer surface of the strip at an angle with respect to a line that is parallel to the major dimension of the strip. The angle is arranged such that when the grip is wrapped about the sports implement, the guideline extends in a direction that is generally perpendicular to the longitudinal axis.

Energy-activated room temperature-pumpable polymer compositions and devices for activating and dispensing the same

Bispecific molecules with clinical application

Method and apparatus for identifying, classifying, or quantifying dna sequences in a sample without sequencing

This invention provides methods by which biologically derived DNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification. Several alternative embodiments are described which are capable of increased discrimination and which use TypeIIS restriction endonucleases, various capture moieties, or samples of specially synthesized cDNA. Another embodiment of the invention uses information on the presence or absence of carefully chosen target subsequences in a single sequence clone together with DNA sequence databases to determine the clone sequence. Computer implemented methods are provided to analyze the experimental results and to determine the sample sequences in question and to carefully choose target subsequences in order that experiments yield a maximum amount of information.

Active agent combination, useful e.g. as an active substance against bacteria, fungus and virus and as deodorant or antiperspirant, comprises epsilon-polylysine and aromatic esters with terpene structure

Active agent combination comprises epsilon -polylysine and one or more aromatic esters with terpene structure. ACTIVITY : Antibacterial; Fungicide; Virucide. MECHANISM OF ACTION : None given.

Soy polysaccharide ethers

Soy polysaccharide ether compounds are disclosed herein comprising uncharged, anionic, and/or cationic organic groups. The degree of substitution of one or more ether compounds is about 0.0025 to about 3.0. Also disclosed are methods of producing these soy polysaccharide ether compounds, as well as methods of their use for increasing the viscosity of aqueous compositions. Compositions comprising ether compounds are also disclosed.

Microprocessor with integrated CPU, RAM, timer, bus arbiter data for communication system

A microprocessor device used as an adapter for a communications loop of the closed-ring, token-passing, local area network type. Each station on the ring has a host processor with a host CPU, a main memory, and a system bus. The microprocessor device, operating relatively independent of the host CPU, is coupled to the main memory by the system bus and includes a local CPU, a local read/write memory, an on-chip timer, a local bus and a bus arbiter. A transmit/receive controller is connected between the ring and the microprocessor device. This controller is coupled to the local bus to directly access the local read/write memory, also under control of the bus arbiter. The local CPU executes instructions fetched from a ROM accessed by the local bus, so the local CPU instruction fetch, the direct memory access from the transmit/receive controller for transmitting or receiving data frames, and the access from the host CPU for copying transmitted or received message frames, all contend for the local bus. Bus arbitration with appropriate priorities is used to control access to the local bus. The on-chip timer accessed by the local bus provides the time period used to monitor and control the communications protocol.

Two-piece funnel with long, ribbed spout

Anti-IL-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Sequestration of carbon dioxide with hydrogen to useful products

Provided herein are genetically engineered microbes that include at least a portion of a carbon fixation pathway, and in one embodiment, use molecular hydrogen to drive carbon dioxide fixation. In one embodiment, the genetically engineered microbe is modified to convert acetyl CoA, molecular hydrogen, and carbon dioxide to 3-hydroxypropionate, 4-hydoxybutyrate, acetyl CoA, or the combination thereof at levels greater than a control microbe. Other products may also be produced. Also provided herein are cell free compositions that convert acetyl CoA, molecular hydrogen, and carbon dioxide to 3-hydroxypropionate, 4- hydoxybutyrate, acetyl CoA, or the combination thereof. Also provided herein are methods of using the genetically engineered microbes and the cell free compositions.

Solid supports for nucleic acid hybridization assays

Compositions and methods for covalently immobilizing an oligonucleotide onto a polymer-coated solid support or similar structure are provided. Specifically, the polymer-coated support, such as a bead, possesses a large number of activatable moieties, preferably primary and secondary amines. An oligonucleotide is activated with a monofunctional or multifunctional reagent, preferably the homotrifunctional reagent cyanuric chloride. The resultant covalently immobilized oligonucleotides on the support serve as nucleic acid probes, and hybridization assays can be conducted wherein specific target nucleic acids are detected in complex biological samples. The beads or similar structures can be employed free in solution, such as in a microtiter well format; in a flow-through format, such as in a column; or in a dipstick. Additionally, dichlorotriazine oligonucleotides and processes for activating oligonucleotides by treatment with cyanuric chloride and derivatives are included in the present invention.

Peptide linkers for improved oligonucleotide delivery

A covalently linked conjugate of an oligonucleotide (ODN) with a peptide and a carrier or targeting ligand (ODN-peptide-carrier) includes a therapeutic oligonucleotide which is capable of selectively binding to a target sequence of DNA, RNA or protein inside a target cell. The ODN is covalently linked to a peptide which is capable of being cleaved by proteolytic enzymes inside the target cell. The peptide, in turn is covalently linked to a carrier or targeting ligand moiety which facilitates delivery of the entire ODN-peptide-carrier conjugate into the cell, and preferably into a specific target tissue type. Inside the cell, the peptide is cleaved, releasing the ODN which, by binding to the target DNA, RNA or protein sequence, brings about a beneficial result.

Mutant hpgg motif and hdash motif delta-5 desaturases and their use in making polyunsaturated fatty acids

Mutant delta 5 desaturases, having the ability to convert dihomo-gamma-linolenic acid [DGLA; 20:3 omega-6] to arachidonic acid [ARA; 20:4 omega-6] and/or eicosatetraenoic acid [ETA; 20:4 omega-3] to eicosapentaenoic acid [EPA; 20:5 omega-3] and possessing at least one mutation within the HPGG (SEQ ID NO:7) motif of the cytochome b 5 -like domain and at least one mutation within the HDASH (SEQ ID NO:8) motif are disclosed. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta 5 desaturases, along with a method of making long chain polyunsaturated fatty acids ["PUFAs"], are also disclosed.

MUTANT ACYL-CoA:LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES

Mutant acyl-CoA:lysophosphatidylcholine acyltransferases ["LPCATs"] having the ability to convert acyl-CoA + 1-acyl- sn -glycero-3-phosphocholine to CoA + 1,2-diacyl- sn -glycero-3-phosphocholine (EC 2.3.1.23) are disclosed herein. Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding mutant LPCATs, along with a method of making long chain polyunsaturated fatty acids ["PUFAs"] using these mutant LPCATs in oleaginous yeast, are also disclosed.

Bispecific reagents for AIDS treatment

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibody nucleic acid molecules and methods

Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Methods of treating conditions using anti-IL-6 antibodies

Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.

Anti-IL-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Pen-injector device containing anti-IL-6 antibodies

A pen-injector device comprising an anti-IL-6 antibody with a liquid formulation have applications in diagnostic and/or therapeutic compositions, methods and devices.

Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody

Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Anti-il-6 antibodies, compositions, methods and uses

Anti-IL-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

ISOLATED IL-6 ANTIBODY, ISOLATED NUCLEIC ACID MOLECULE AND VECTOR, TRANSGENIC MICRO-ORGANISM HOST CELL, METHOD FOR PRODUCING AN IL-6 ANTIBODY, COMPOSITION INCLUDING ISOLATED IL-6 ANTIBODY, AND AN IL-6 ANTIBODY COMPRISING A MEDICAL DEVICE FOR PHARMACEUTICAL OR HUMAN DIAGNOSTIC USE

anticorpo il-6 isolado, anticorpo humano isolado projetado, anticorpo humano isolado ou humano projetado, molécula e vetor de ácido nucléico isolado, método para a produção de um anticorpo il-6, composição compreendendo o anticorpo il-6 isolado, anticorpo ou fragmento antiidiótipo, uso do referido anticorpo, dispositivo médico que compreende um anticorpo il-6 e artigo fabricado para uso farmacêutico ou diagnóstico humano. a presente invenção se refere a um anticorpo anti-il-6, incluindo ácidos nucléicos isolados que codificam pelo menos um anticorpo anti-il-6, vetores, células hospedeiras, animais ou plantas transgênicas e métodos de fabricação e utilização destes têm aplicações em composições, métodos e dispositivos diagnósticos e/ou terapêuticos. isolated IL-6 antibody, isolated designed human antibody, isolated human or designed human antibody, isolated nucleic acid molecule and vector, method for producing an IL-6 antibody, composition comprising the isolated IL-6 antibody, antibody or anti-idiotype fragment , use of said antibody, medical device comprising a IL-6 antibody, and article of manufacture for human pharmaceutical or diagnostic use. the present invention relates to an anti-il-6 antibody, including isolated nucleic acids encoding at least one anti-il-6 antibody, vectors, host cells, transgenic animals or plants and methods of making and using these have applications in compositions , diagnostic and/or therapeutic methods and devices.

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies, compounds methods and uses

Un anticuerpo IL-6 aislado que incluye: (i) Una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: 101 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 103; (ii) Una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: 124 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 126; (iii) Una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: l16 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 118; (iv) Una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: 120 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 122; (v) Una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: 128 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 130; o (vi) una secuencia de aminoácido de región variable de cadena ligera con Nº DE ID DE SEC: 97 y una secuencia de aminoácido de región variable de cadena pesada con Nº DE ID DE SEC: 99. An isolated IL-6 antibody that includes: (i) A light chain variable region amino acid sequence with SEQ ID NO: 101 and a heavy chain variable region amino acid sequence with SEQ ID NO: 103; (ii) A light chain variable region amino acid sequence with SEQ ID NO: 124 and a heavy chain variable region amino acid sequence with SEQ ID NO: 126; (iii) A light chain variable region amino acid sequence with SEQ ID NO: 11 and a heavy chain variable region amino acid sequence with SEQ ID NO: 118; (iv) A light chain variable region amino acid sequence with SEQ ID NO: 120 and a heavy chain variable region amino acid sequence with SEQ ID NO: 122; (v) A light chain variable region amino acid sequence with SEQ ID NO: 128 and a heavy chain variable region amino acid sequence with SEQ ID NO: 130; or (vi) a light chain variable region amino acid ...

Anti-il-6 antibodies, compositions, methods and uses

Humanized anti-IL-6 antibodies, compositions, methods and uses

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-il-6 antibodies, compositions, methods and uses

Anti-il-6 antibodies, compositions, methods and uses

Izolovano anti-IL-6 antitelo koje sadrži: (i) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu Identifikacionim brojem sekvence (SEQ ID NO): 101 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 103; (ii) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu kao SEQ ID NO: 124 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 126; (iii) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu kao SEQ ID NO: 116 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 118; (iv) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu kao SEQ ID NO: 120 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 122; (v) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu kao SEQ ID NO: 128 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 130; ili (vi) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenu kao SEQ ID NO: 97 i aminokiselinsku sekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 99. Prijava sadrži još 20 patentnih zahteva. Isolated anti-IL-6 antibody comprising: (i) the amino acid sequence of the light chain variable region labeled Sequence Identification Number (SEQ ID NO): 101 and the amino acid sequence of the heavy chain variable region designated SEQ ID NO: 103; (ii) the amino acid sequence of the light chain variable region designated SEQ ID NO: 124 and the amino acid sequence of the heavy chain variable region designated SEQ ID NO: 126; (iii) the amino acid sequence of the light chain variable region designated SEQ ID NO: 116 and the amino acid sequence of the heavy chain variable region designated SEQ ID NO: 118; (iv) the amino acid sequence of the light chain variable region designated SEQ ID NO: 120 and the amino acid sequence of the heavy chain variable region designated SEQ ID NO: 122; (v) the ...

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Humanized anti-IL-6 antibodies, compositions, methods and uses

Humanized anti-IL-6 antibodies, compositions, methods and uses

Humanized anti-IL-6 antibodies, compositions, methods and uses

Un anticuerpo anti IL-6 aislado, con regiones marco y constantes completamente humanas, que comprende: (i) una región variable de cadena ligera, que comprende una secuencia de aminoácidos de la cadena ligera de la región determinante de la complementariedad 1 (CDRL1) de la SEC ID Nº:3, una secuencia de aminoácidos de la CDRL2 de la SEC ID Nº:21, una secuencia de aminoácidos de la CDRL3 de la SEC ID Nº:29, y una región variable de la cadena pesada, que comprende una secuencia de aminoácidos de la cadena pesada de la región determinante de la complementariedad 1 (CDRH1) de la SEC ID Nº:39, una secuencia de aminoácidos de la CDRH2 de la SEC ID Nº:59, y una secuencia de aminoácidos de la CDRH3 de la SEC ID Nº:89; o (ii) una región variable de cadena ligera, en la que la CDRL1 comprende la secuencia de aminoácidos de la de la SEC ID Nº:3, la CDRL2 comprende la secuencia de aminoácidos de la de la SEC ID Nº:21, la CDRL3 comprende la secuencia de aminoácidos de la SEC ID Nº:29, y una región variable de la cadena pesada en la que la CDRH1 comprende la secuencia de aminoácidos de la SEC ID Nº:41, la CDRH2 comprende la secuencia de aminoácidos de la SEC ID Nº:75, y la CDRH3 comprende la secuencia de aminoácidos de la SEC ID Nº:89; o iii) una región variable de cadena ligera, en la que la CDRL1 comprende la secuencia de aminoácidos de la de la SEC ID Nº:15, la CDRL2 comprende la secuencia de aminoácidos de la de la SEC ID Nº:27, la CDRL3 comprende la secuencia de aminoácidos de la SEC ID Nº:35, y una región variable de la cadena pesada en la que la CDRH1 comprende la secuencia de aminoácidos de la SEC ID Nº:47, la CDRH2 comprende la secuencia de aminoácidos de la SEC ID Nº:57, y la CDRH3 comprende la secuencia de aminoácidos de la SEC ID Nº:91; o iv) una región variable de cadena ligera, en la que la CDRL1 comprende la secuencia de aminoácidos de la de la SEC ID Nº:15, la CDRL2 comprende la secuencia de aminoácidos de la de la SEC ID Nº:17, la CDRL3 comprende la secuencia de ...

Humanized anti-il-6 antibodies, compositions, methods and uses

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies

Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.

Anti-IL-6 antibodies, compositions, methods and uses

Anti-il-6 antibodies, compositions, methods and uses

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 Antibody Nucleic Acid Molecules and Methods

Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Anti-IL-6 antibodies, compositions, methods and uses

Abstract An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof and having applications in diagnostic and/or therapeutic compositions, 5 methods and devices.

Master slave arrangement for electronic engine control equipment of internal combustion engine i.e. diesel engine, of vehicle, has motor identification module inseparably arranged at crank case of engine

Vorgeschlagen wird eine Master-Slaveanordnung (1) eines elektronischen Motorsteuergeräts (2) mit einem Motoridentifikationsmodul (3), bei der das elektronische Motorsteuergerät (2) die Brennkraftmaschine steuert und regelt, bei der das Motoridentifizierungsmodul (3) zumindest einen Mikroprozessor und einen Speicherbaustein zur Speicherung einer Motoridentifikation sowie Motorspezifika enthält und bei der das elektronische Motorsteuergerät (2) und das Motoridentifikationsmodul (3) über einen Motorkabelbaum (4) Daten austauschen. Die Erfindung ist dadurch gekennzeichnet, dass das Motoridentifikationsmodul (3) unlösbar am Kurbelgehäuse (5) der Brennkraftmaschine angeordnet ist und das Motoridentifikationsmodul (3) nur unter Zerstörung vom Kurbelgehäuse (5) sowie vom Motorkabelbaum (4) trennbar ist.

Method for operating an internal combustion engine, internal combustion engine and maintenance system for an internal combustion engine, self-executable computer program product and non-volatile storage medium

Die Erfindung betrifft ein Verfahren zum Betrieb, insbesondere zur Wartung, einer Brennkraftmaschine 100 mit einem Motor 20) mit einer Hardware-Struktur 10 umfassend ein Motorsteuergerät 2 und eine Wartungseinheit 1, mit einem elektronischen Motoridentifikationsmodul 3 und mit einem Motorsteuerprogramm, insbesondere umfassend eine Firmware FW und eine funktionalen Motorapplikation FSW, aufweisend die Schritte: Bereitstellen eines Computerprogrammprodukts über ein Netzwerk 80 mittels dem eine Motoridentifikation und Motordaten zusammenladbar und austauschbar sind, wobei das Computerprogrammprodukt ausgebildet ist zum Austauschen, insbesondere Up- und/oder Downloaden, eines Wartungssoftwaremoduls 60, mittels dem die Motoridentifikation und die Motordaten zusammenstellbar sind; Überspielen des Computerprogrammprodukts auf ein nichtflüchtiges Speichermedium 30; Koppeln des nichtflüchtigen Speichermediums 30 an die Wartungseinheit 1 der Hardware-Struktur 10 und Ausführen des Computerprogrammprodukts unter Austauschen des Wartungssoftwaremoduls 60 zwischen dem nichtflüchtigen Speichermedium 30 und der Wartungseinheit 1; Identifikation des Motors und Zusammenstellen von Motordaten mittels dem Wartungssoftwaremodul 60 und einer Hardware-Komponente der Hardware-Struktur 10. The invention relates to a method for operating, in particular for maintenance, an internal combustion engine 100 with a motor 20) having a hardware structure 10 comprising an engine control unit 2 and a maintenance unit 1, with an electronic engine identification module 3 and with a motor control program, in particular comprising a firmware FW and a functional engine application FSW, comprising the steps of: providing a computer program product via a network 80 by means of which a motor identification and motor data are loadable and interchangeable, wherein the computer program product is adapted for exchanging, in particular uploading and / or downloading, a maintenance software module 60, by means of ...

Master/slave arrangement of an electronic engine control device with engine identification module

A master/slave arrangement of an electronic engine control device with an engine identification module. The electronic engine control device controls and regulates the internal combustion machine. The engine identification module includes at least one microprocessor and a memory building block for storing an engine identification as well as engine specifics. The electronic engine control device and the engine identification module exchange data through an engine cable harness. The engine identification module is arranged inseparably at the crank housing of the internal combustion machine. The engine identification module can be removed from the crank housing as well as from the engine cable harness only by being destroyed.

Method for operating an internal combustion engine, internal combustion engine and maintenance system for an internal combustion engine, self-executable computer program product and non-volatile storage medium

A method for operating an internal combustion engine having a hardware structure including an engine control unit and a maintenance unit, an electronic engine identification module and an engine control program, the method having the steps: providing a computer program product via a network by which an engine identification and engine data are loaded together and are exchanged, wherein the computer program product is designed for uploading and/or downloading a maintenance software module by which the engine identification and the engine data are compiled; loading the computer program product onto a non-volatile storage medium; coupling the non-volatile storage medium to the maintenance unit of the hardware structure and executing the computer program product; exchanging the maintenance software module between the non-volatile storage medium and the maintenance unit; identifying the engine and compiling engine data by the maintenance software module and a hardware component of the hardware structure.

Fluorescent detector systems for the detection of chemical perturbations in sterile storage devices

System and method for detecting and measuring chemical perturbations in a sample. The system and method are useful for non-invasive pH monitoring of blood or blood products sealed in storage bags.

Treatment of neuromuscular disorders and conditions with different botulinum serotype

A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.

Method of enhancing immune responses to herpes simplex virus vaccine

A method for inducing and enhancing protective and/or therapeutic immunity in a mammal to HSV includes the steps of at least one immunization with an effective amount of a DNA vaccine composition which comprises a first nucleic acid molecule comprising a DNA sequence encoding the HSV type 1 or type 2 gD protein, and a second nucleic acid molecule comprising a DNA sequence encoding each Interleukin-12 heterodimer subunit. The method also comprises at least one subsequent immunization with an effective amount of a protein vaccine composition which comprises the HSV type 1 or type 2 gD protein; and the IL-12 heterodimer. A local anesthetic may be included in the DNA vaccine composition in an amount that forms one or more complexes with the nucleic acid molecules. When provided to the mammal in suitable effective dosages according to this protocol, the vaccine compositions used in this method produce an unexpectedly good protective and/or therapeutic immune response against HSV in an immunized mammal.

Scissors and the like

Edging strip for furniture

Die Erfindung betrifft eine Kantenleiste (1) für Möbelstücke, umfassend eine Schmelzschicht (3) und eine mit der Schmelzschicht (3) verbundene Strukturschicht (2), die beide wenigstens teilweise einen polymeren Werkstoff aufweisen, wobei die Schmelzschicht (3) Zusatzstoffe enthält, die sich dadurch auszeichnet, dass die Schmelzschicht (3) wenigstens einen eine Verfärbung verursachenden, wenigstens teilweise anorganische und/oder organische Pigmente enthaltenden, Zusatzstoff in einer Menge von etwa 0,01 bis 10 Gew.-%, bevorzugt 0,02 bis 5 Gew.-%, bezogen auf ihr Gesamtgewicht, aufweist. The invention relates to an edge strip (1) for furniture, comprising a melt layer (3) and a structural layer (2) connected to the melt layer (3), both of which at least partially comprise a polymeric material, the melt layer (3) containing additives which characterized in that the melt layer (3) contains at least one causing a discoloration, at least partially inorganic and / or organic pigments containing additive in an amount of about 0.01 to 10 wt .-%, preferably 0.02 to 5 wt. %, based on their total weight.

Method for treating a mucus secretion

The present invention provides a method for relieving pain, associated with muscle contractions, a composition and a method of treating conditions such as cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretions and a method for treating smooth muscle disorders including, but not limited to, spasms in the sphincter of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of Botulinum toxin selected from a group consisting of Botulinum toxin types B, C, D, E, F and G.

Apparatus, method and system for managing session encapsulation information within an internet protocol content bypass architecture

An apparatus, method and system for delivering Internet Protocol (IP) content within a system that includes a bypass architecture, using a Session Encapsulation Information Database (SEIDB). Within an existing PacketCable Multimedia (PCMM) framework used as a control plane for IP content bypass flow setup, the SEIDB system stores session bypass encapsulation information for IP content bypass flows within the system. Within the SEIDB, each entry of bypass encapsulation information has a flow classifier component that uniquely identifies a bypass flow in a manner that allows both a cable modem termination system (CMTS) and the IP content source to uniquely identify the bypass flow at the SEIDB. Initially, the CMTS gathers bypass encapsulation information and uploads it to the SEIDB. Before the bypass flow begins, the IP content source obtains the necessary bypass encapsulation information from the SEIDB, e.g., using a flow classifier as a search filter item.

Small/special media guide-in tray

A small or special media guide-in tray including a media tray, an aperture disposed in the media tray, first and second opposed guide arms extending through the aperture and biased to a first position. The first and second opposed guide arms are pivotally mounted and are synchronously movable when small media is inserted. The opposed guide arms and biasing are used to automatically center the small media as it is inserted between the guide arms. The guide-in tray may be utilized with media handling devices having an L-path media feed wherein the guide-in media tray is incorporated in an input tray or in a C-path media feed wherein the guide-in media tray is incorporated in an exit tray.

Pouch construction

Apparatus for enabling the use of a computer mouse at a sterile surgical site comprises a pouch for the accommodation of the mouse and an inlet sleeve forming an inlet passage into the pouch. The pouch and sleeve are formed of pliable, preferably transparent sterilizable material. When the mouse has been admitted to the pouch via the passage, the sleeve may be separated from the pouch and the open mouth of the latter rolled to form a seal, thereby retaining the mouse within the pouch.

System for segmenting large files in an SMTP network including a digital input scanner

In a digital scanner or other source for sending documents by electronic mail to a client, the size of the document is determined and a calculation is made of how many segments the document must be divided into. If the required number of segments is so large as to present a risk of flooding a network, a warning is displayed to a user. The system is particularly useful in the context of scanning to e-mail full-color images.

Receptacle for the separation of tumor cells

The invention relates to a receptacle (1) for separating tumor cells, especially disseminated tumor cells (9), from a biological sample, comprising a closed end (2) and an end (3) that can be opened. Said receptacle (1) contains a thixotropic substance (4) having a specific density ranging from a minimum of 1.055 g/cm<SUP>3</SUP>, preferably 1.057 g/cm<SUP>3</SUP>, particularly 1.060 g/cm<SUP>3</SUP>, to a maximum of 1.070 g/cm<SUP>3</SUP>, preferably 1.069 g/cm<SUP>3</SUP>, especially 1.065 g/cm<SUP>3</SUP>, and an optional separating medium (5) in the form of a density gradient having a specific density ranging from a minimum of 1.060 g/cm<SUP>3</SUP>, preferably 1.065 g/cm<SUP>3</SUP>, particularly 1.070 g/cm<SUP>3</SUP>, and a maximum of 1.085 g/cm<SUP>3</SUP>, preferably 1.080 g/cm<SUP>3</SUP>, especially 1.075 /cm<SUP>3</SUP>.

Plants with altered cell wall biosynthesis and methods of use

Provided herein are plants having altered expression of a GAUT polypeptide. Such plants have phenotypes that may include decreased recalcitrance, increased growth, decreased lignin content, or a combination thereof. Also provided herein are methods of making and using such plants.

Providing a portion of an electronic mail message based upon a transfer rate, a message size, and a file format

Updating authentication server lists for users accessing shared access devices

A method, service, system, computer program, etc., provides a list of acceptable authentication servers that a user could use to log in when accessing a networked device, such as a networked printer or document processing device. The embodiments include preparing a module, such as a dynamically loadable module (DLM) for use in the networked system accessed by the users. Each of the networked devices is enabled to accept the DLM. The embodiments forward the DLM to the networked devices as a print job along a print job submission path within the network. The networked devices recognize the DLM as a special job. Further, the networked devices use the DLM to install the XML file on each of the networked devices. Thus, the authentication server lists and authentication programs are updated within each of the networked devices using the DLM.

Compositions for gut health

Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR). improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

Apparatus, method and system for managing session encapsulation information within an internet protocol content bypass architecture

An apparatus, method and system for delivering Internet Protocol (IP) content within a system that includes a bypass architecture, using a Session Encapsulation Information Database (SEIDB). Within an existing PacketCable Multimedia (PCMM) framework used as a control plane for IP content bypass flow setup, the SEIDB system stores session bypass encapsulation information for IP content bypass flows within the system. Within the SEIDB, each entry of bypass encapsulation information has a flow classifier component that uniquely identifies a bypass flow in a manner that allows both a cable modem termination system (CMTS) and the IP content source to uniquely identify the bypass flow at the SEIDB. Initially, the CMTS gathers bypass encapsulation information and uploads it to the SEIDB. Before the bypass flow begins, the IP content source obtains the necessary bypass encapsulation information from the SEIDB, e.g., using a flow classifier as a search filter item.

Device for testing the material of test objects by means of x-ray radiation

The invention relates to a device (10) for testing the material of test objects (15) by means of X-ray radiation, comprising a translatory conveying device (14) for automatically feeding and removing test objects (15) one after the other, and/or from a test position, an X-ray device (20) comprising an X-ray source (12) for irradiating a test object (15) maintained on a support (33) in the test position, and an X-ray detector (13). Said test object (15) and X-ray device (20) can be rotated in relation to each other only about an essentially vertical rotational axis during X-ray testing. According to one aspect of the invention, for X-ray testing, the support (33) and the test object (15) maintained on said support can be rotated together about the rotational axis (R). According to another aspect of the invention, for X-ray testing, the X-ray device (20) can be rotated about the rotational axis (R).

Sheath for electric warming pads

Coaxial microwave assisted deposition and etch systems

Hair clipper

Fixing device for inserting fixing and connecting units into holders comprises an intermediate layer fixed by negotiable stop along a sliding path for a tool holder

Fixing device (1) comprises an intermediate layer fixed by negotiable stop along a sliding path for a tool holder (3). Preferred Features: A tool (16) inserted into the holder releases a space for the introduction and/or storage of the fixing device during movement into the retreated position in the device head (4).

Ip video delivery using flexible channel bonding

An IP video delivery system and method that allocates a first number of video streams for delivery on a number of channels that, provides a number of bonding groups, where each bonding group bonds at least one of the channels, and allocates a second number of video streams for delivery on the bonding groups. In one aspect, the method delivers the first video streams as unbonded on the channels. The bonding groups utilize bandwidth unused by the first video streams. In one aspect, the method utilizes bandwidth unused by the first or second video streams for high speed data. The method provides instantaneous load balancing to spread the first and second video streams across all available bandwidth in the channels, and delivers those video streams using a variable bit rate with no additional statistical multiplexing rate shaping to fit video streams into the channels.

Method of quantifying tumour cells in a body fluid and a suitable test kit

The disclosure relates to a method of quantifying tumour cells in a body fluid. A reaction is first carried out with the sample under investigation by which the RNA component of the telomerase is specifically amplified. The quantity of amplified nucleic acid is then quantitatively determined. Also disclosed are suitable test kits.

Method for treating headache

The present invention provides a method for relieving pain, associated with muscle contractions, a composition and a method of treating conditions such as cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretions and a method for treating smooth muscle disorders including, but not limited to, spasms in the sphincter of the cardiovascular arteriole, gastrointestinal system, urinary, gall bladder and rectum, which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of Botulinum toxin selected from a group consisting of Botulinum toxin types B, C, D, E, F and G.

Process for the production of ethanol

ABSTRACT Ethanol is produced by carbonylation of methanol by reaction with carbon monoxide in the presence of a carbonylation catalyst to form acetic acid which is then converted to an acetate ester followed by hydrogenolysis of the acetate ester formed to give ethanol or a mixture of ethanol and another alcohol which can be separated by distillation. Preferably the other alcohol or part of the ethanol recovered from the hydrogenolysis step is recycled for further esterification. Carbonylation can be effected-using a CO/H2 mixture and hydrogenolysis can similarly be conducted in the presence of carbon monoxide, leading to the possibility of circulating gas between the carbonylation and hydrogenolysis zones with synthesis gas, preferably a 2:1 H2:CO molar mixture being used as make up gas.

Botulinum toxin A or B for the treatment of pain associated with smooth muscle spasms

Nanolipidic particles

Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

Sadiron sole plate

Method of quantifying tumour cells in a body fluid and a suitable test kit

The disclosure relates to a method of quantifying tumour cells in a body fluid. A reaction is first carried out with the sample under investigation by which the RNA component of the telomerase is specifically amplified. The quantity of amplified nucleic acid is then quantitatively determined. Also disclosed are suitable test kits.

Apparatus, method and system for managing session encapsulation information within an internet protocol content bypass architecture

An apparatus, method and system for delivering Internet Protocol (IP) content within a system that includes a bypass architecture, using a Session Encapsulation Information Database (SEIDB). Within an existing PacketCable Multimedia (PCMM) framework used as a control plane for IP content bypass flow setup, the SEIDB system stores session bypass encapsulation information for IP content bypass flows within the system. Within the SEIDB, each entry of bypass encapsulation information has a flow classifier component that uniquely identifies a bypass flow in a manner that allows both a cable modem termination system (CMTS) and the IP content source to uniquely identify the bypass flow at the SEIDB. Initially, the CMTS gathers bypass encapsulation information and uploads it to the SEIDB. Before the bypass flow begins, the IP content source obtains the necessary bypass encapsulation information from the SEIDB, e.g., using a flow classifier as a search filter item.

System and method for transmitting digital content using cable modem termination system (CMTS) bypass architecture

System and method for controlling ion density and energy using modulated power signals

Botulinum toxins for treating dystonia

This invention provides the use of botulinum toxin type B for the manufacture of a medicament for treating a dystonia such as tardive dyskinesia, spasmodic torticollis, essential tremor or spasmodic dysphonia.

Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein

The invention relates to a method for preparing a primary sample (3) of biological origin in order to determine at least one constituent contained therein. According to the invention, the primary sample (3) is contained in a first container (1) and at least one part of said primary sample (3) is transferred from the first container (1) into at least one reaction container. A reagent (9) or a reagent mixture for treating the primary sample (3) or the constituent to be determined is placed in at least one of the reaction containers. In order to transfer the at least one part of the primary sample (3), at least two respective containers (1,6) are interconnected to form a hermetically sealed system until the constituent(s) to be determined are stabilised at room temperature by means of a reaction with a reagent (9) or a reagent mixture.

Traffic network flow control using dynamically modified metrics for redundancy connections

Distance vector routing protocols such as the Routing Information Protocol fail to rapidly reconfigure to use redundant links. By modifying the outgoing advertised hop count (31) upon detecting a failure in a connection (32) for which a backup or redundant connection exists, incoming traffic is diverted to the redundant or backup connection (33). An artificially high hop count (31) is advertised for a given port, and when a failure or loss of reachability occurs in a connection associated with that port (32), an advertisement of a lower hop count on the backup or redundant connection for the given port is triggered (33). This causes rapid rerouting of incoming traffic to the backup or redundant connection.

Edging strip for furniture

Die Erfindung betrifft eine Kantenleiste (1) für Möbelstücke, umfassend eine Schmelzschicht (3) und eine mit der Schmelzschicht (3) verbundene Strukturschicht (2), die beide wenigstens teilweise einen polymeren Werkstoff aufweisen, wobei die Schmelzschicht (3) Zusatzstoffe enthält, die sich dadurch auszeichnet, dass die Schmelzschicht (3) wenigstens einen eine Verfärbung verursachenden, wenigstens teilweise anorganische und/oder organische Pigmente enthaltenden, Zusatzstoff in einer Menge von etwa 0,01 bis 10 Gew.-%, bevorzugt 0,02 bis 5 Gew.-%, bezogen auf ihr Gesamtgewicht, aufweist. The invention relates to an edge strip (1) for furniture, comprising a melt layer (3) and a structural layer (2) connected to the melt layer (3), both of which at least partially comprise a polymeric material, the melt layer (3) containing additives which characterized in that the melt layer (3) contains at least one causing a discoloration, at least partially inorganic and / or organic pigments containing additive in an amount of about 0.01 to 10 wt .-%, preferably 0.02 to 5 wt. %, based on their total weight.